<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00678327</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000593562</org_study_id>
    <secondary_id>CRUK-2007-006064-30</secondary_id>
    <secondary_id>CRUK-07/146</secondary_id>
    <nct_id>NCT00678327</nct_id>
  </id_info>
  <brief_title>Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma</brief_title>
  <official_title>A Randomized Phase III Trial to Assess Response Adapted Therapy Using FDG-PET Imaging in Patients With Newly Diagnosed, Advanced Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Research UK &amp; UCL Cancer Trials Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Imaging procedures, such as fludeoxyglucose F 18 (FDG)-PET/CT scan, done before,&#xD;
      during, and after chemotherapy may help doctors assess a patient's response to treatment and&#xD;
      help plan the best treatment. It is not yet known whether FDG-PET/CT imaging is effective in&#xD;
      assessing response to chemotherapy in patients with newly diagnosed Hodgkin lymphoma.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying FDG-PET/CT imaging to see how well it&#xD;
      works in assessing response to chemotherapy in patients with newly diagnosed stage II, stage&#xD;
      III, or stage IV Hodgkin lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To determine if fludeoxyglucose F 18 (FDG)-PET/CT imaging can be reproducibly and&#xD;
           effectively applied in the early assessment of response to chemotherapy in patients with&#xD;
           newly diagnosed stage II-IV Hodgkin lymphoma.&#xD;
&#xD;
        -  To determine if a negative FDG-PET/CT scan after 2 courses of ABVD chemotherapy&#xD;
           comprising doxorubicin hydrochloride, bleomycin, vinblastine, and dacarbazine can be&#xD;
           used to predict a group of patients for whom it is safe to reduce therapy by the&#xD;
           subsequent omission of bleomycin, without detriment to progression-free survival.&#xD;
&#xD;
        -  To determine if treatment intensification in response to positive FDG-PET/CT imaging&#xD;
           after 2 courses of ABVD chemotherapy can improve the outcome by comparison with previous&#xD;
           series.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients undergo fludeoxyglucose F 18 (FDG)-PET/CT imaging at baseline. Patients then receive&#xD;
      ABVD chemotherapy comprising doxorubicin hydrochloride IV, bleomycin IV, vinblastine IV, and&#xD;
      dacarbazine IV on days 1 and 15. Treatment repeats every 28 days for up to 2 courses in the&#xD;
      absence of disease progression or unacceptable toxicity. Between days 22 and 25 of course 2,&#xD;
      patients undergo a second FDG-PET/CT scan to assess response. Subsequent therapy is based on&#xD;
      FDG-PET/CT scan results.&#xD;
&#xD;
        -  Negative FDG-PET/CT scan: Patients with a negative FDG-PET/CT scan are randomized to 1&#xD;
           of 2 treatment arms.&#xD;
&#xD;
             -  Arm I (ABVD chemotherapy): Patients receive ABVD chemotherapy comprising&#xD;
                doxorubicin hydrochloride IV, bleomycin IV, vinblastine IV, and dacarbazine IV on&#xD;
                days 1 and 15. Treatment repeats every 28 days for up to 4 courses in the absence&#xD;
                of disease progression or unacceptable toxicity.&#xD;
&#xD;
             -  Arm II (AVD chemotherapy): Patients receive AVD chemotherapy comprising doxorubicin&#xD;
                hydrochloride IV, vinblastine IV, and dacarbazine IV on days 1 and 15. Treatment&#xD;
                repeats every 28 days for up to 4 courses in the absence of disease progression or&#xD;
                unacceptable toxicity.&#xD;
&#xD;
        -  Positive FDG-PET/CT scan: Patients with a positive FDG-PET/CT scan are assigned to 1 of&#xD;
           2 chemotherapy regimens, as determined by the participating center.&#xD;
&#xD;
             -  BEACOPP-14 chemotherapy: Patients receive doxorubicin hydrochloride IV and&#xD;
                cyclophosphamide IV on day 1; etoposide IV on days 1-3; oral procarbazine&#xD;
                hydrochloride and oral prednisolone on days 1-7; and bleomycin IV and vincristine&#xD;
                IV on day 8. Patients also receive filgrastim (G-CSF) subcutaneously (SC) on days&#xD;
                8-13 OR pegfilgrastim SC once on day 8. Treatment repeats every 14 days for up to 4&#xD;
                courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
             -  BEACOPP-escalated chemotherapy: Patients receive doxorubicin hydrochloride IV and&#xD;
                cyclophosphamide IV on day 1; etoposide IV on days 1-3; oral procarbazine&#xD;
                hydrochloride on days 1-7; oral prednisolone on days 1-14; and bleomycin IV and&#xD;
                vincristine IV on day 8. Patients also receive G-CSF SC beginning on day 8 and&#xD;
                continuing until blood counts recover OR pegfilgrastim SC once on day 8. Treatment&#xD;
                repeats every 21 days for up to 3 courses in the absence of disease progression or&#xD;
                unacceptable toxicity.&#xD;
&#xD;
      After completion of BEACOPP chemotherapy, patients undergo a third FDG-PET/CT scan to assess&#xD;
      response. Patients with a negative FDG-PET/CT scan receive 2 more courses of BEACOPP-14 or 1&#xD;
      more course of BEACOPP-escalated chemotherapy. Patients with a persistently positive&#xD;
      FDG-PET/CT scan may receive radiotherapy to sites of FDG uptake or salvage chemotherapy, at&#xD;
      the investigator's discretion.&#xD;
&#xD;
      After completion of study therapy, patients are followed every 3 months for 1 year, every 4&#xD;
      months for 2 years, every 6 months for 2 years, and then annually thereafter.&#xD;
&#xD;
      Peer Reviewed and Funded or Endorsed by Cancer Research UK.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 29, 2008</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Actual">January 31, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-year progression-free survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years after last patient recruited</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute and chronic toxicity as assessed by NCI CTCAE v3.0</measure>
    <time_frame>5 years after last patient recruited</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1202</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive ABVD chemotherapy comprising doxorubicin hydrochloride IV, bleomycin IV, vinblastine IV, and dacarbazine IV on days 1 and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive AVD chemotherapy comprising doxorubicin hydrochloride IV, vinblastine IV, and dacarbazine IV on days 1 and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BEACOPP-14 chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1; etoposide IV on days 1-3; oral procarbazine hydrochloride and oral prednisolone on days 1-7; and bleomycin IV and vincristine IV on day 8. Patients also receive filgrastim (G-CSF) subcutaneously (SC) on days 8-13 OR pegfilgrastim SC once on day 8. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BEACOPP-escalated chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1; etoposide IV on days 1-3; oral procarbazine hydrochloride on days 1-7; oral prednisolone on days 1-14; and bleomycin IV and vincristine IV on day 8. Patients also receive G-CSF SC beginning on day 8 and continuing until blood counts recover OR pegfilgrastim SC once on day 8. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bleomycin sulfate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>BEACOPP-14 chemotherapy</arm_group_label>
    <arm_group_label>BEACOPP-escalated chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>Given subcutaneously</description>
    <arm_group_label>BEACOPP-14 chemotherapy</arm_group_label>
    <arm_group_label>BEACOPP-escalated chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pegfilgrastim</intervention_name>
    <description>Given subcutaneously</description>
    <arm_group_label>BEACOPP-14 chemotherapy</arm_group_label>
    <arm_group_label>BEACOPP-escalated chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>BEACOPP-14 chemotherapy</arm_group_label>
    <arm_group_label>BEACOPP-escalated chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dacarbazine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>BEACOPP-14 chemotherapy</arm_group_label>
    <arm_group_label>BEACOPP-escalated chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>BEACOPP-14 chemotherapy</arm_group_label>
    <arm_group_label>BEACOPP-escalated chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisolone</intervention_name>
    <description>Given orally</description>
    <arm_group_label>BEACOPP-14 chemotherapy</arm_group_label>
    <arm_group_label>BEACOPP-escalated chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>procarbazine hydrochloride</intervention_name>
    <description>Given orally</description>
    <arm_group_label>BEACOPP-14 chemotherapy</arm_group_label>
    <arm_group_label>BEACOPP-escalated chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinblastine sulfate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>BEACOPP-14 chemotherapy</arm_group_label>
    <arm_group_label>BEACOPP-escalated chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed classical Hodgkin lymphoma (HL) meeting the following&#xD;
             criteria:&#xD;
&#xD;
               -  Meets current WHO classification criteria (i.e., nodular sclerosis, mixed&#xD;
                  cellularity, lymphocyte rich, and lymphocyte-depleted)&#xD;
&#xD;
               -  Clinical stage IIB, III, or IV disease OR clinical stage IIA disease with adverse&#xD;
                  features, including any of the following:&#xD;
&#xD;
                    -  Bulk mediastinal disease, defined as maximal transverse diameter of mass &gt;&#xD;
                       0.33 of the internal thoracic diameter at D5/6 interspace on routine chest&#xD;
                       x-ray&#xD;
&#xD;
                    -  Disease outside the mediastinum and lymph node or lymph node mass &gt; 10 cm in&#xD;
                       diameter&#xD;
&#xD;
                    -  More than two sites of disease&#xD;
&#xD;
                    -  Other poor-risk features that require treatment with full course combination&#xD;
                       chemotherapy&#xD;
&#xD;
          -  Newly diagnosed disease&#xD;
&#xD;
          -  No CNS or meningeal involvement by lymphoma&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-3&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  ANC &gt; 1,500/mm^3 (unless there is bone marrow infiltration by lymphoma)&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3 (unless there is bone marrow infiltration by lymphoma)&#xD;
&#xD;
          -  Creatinine &lt; 150% of upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin &lt; 2.0 times ULN (unless attributed to lymphoma)&#xD;
&#xD;
          -  Transaminases &lt; 2.5 times ULN (unless attributed to lymphoma)&#xD;
&#xD;
          -  LVEF â‰¥ 50% (in patients with a significant history of ischemic heart disease or&#xD;
             hypertension)&#xD;
&#xD;
          -  Diffusion capacity within 25% of normal predicted value by lung function testing&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Amenable to the administration of a full course of chemotherapy, according to the&#xD;
             investigator&#xD;
&#xD;
          -  Must have access to PET/CT scanning&#xD;
&#xD;
          -  No poorly controlled diabetes mellitus&#xD;
&#xD;
          -  No cardiac contraindication to doxorubicin hydrochloride, including abnormal&#xD;
             contractility by ECHO or MUGA&#xD;
&#xD;
          -  No neurological contraindication to chemotherapy (e.g., pre-existing neuropathy)&#xD;
&#xD;
          -  No other concurrent uncontrolled medical condition&#xD;
&#xD;
          -  No other active malignant disease within the past 10 years, except fully excised basal&#xD;
             cell or squamous cell carcinoma of the skin or carcinoma in situ of the uterine cervix&#xD;
&#xD;
          -  No known positivity for HIV, hepatitis B surface antigen, or hepatitis C&#xD;
&#xD;
               -  Routine testing, in the absence of risk factors, is not required&#xD;
&#xD;
          -  No medical or psychiatric condition that compromises the patient's ability to give&#xD;
             informed consent&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior chemotherapy, radiotherapy or other investigational drug for HL&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Johnson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Southampton NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <state>England</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 9, 2008</study_first_submitted>
  <study_first_submitted_qc>May 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2008</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III adult Hodgkin lymphoma</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>adult nodular sclerosis Hodgkin lymphoma</keyword>
  <keyword>adult lymphocyte depletion Hodgkin lymphoma</keyword>
  <keyword>adult lymphocyte predominant Hodgkin lymphoma</keyword>
  <keyword>adult mixed cellularity Hodgkin lymphoma</keyword>
  <keyword>stage II adult Hodgkin lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Bleomycin</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Procarbazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

